Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1860657
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Allarity Therapeutics filed an 8-K on 3/26 for events on 3/25. Check for material updates.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on March 26, 2024, reporting an event on March 25, 2024. The filing is related to Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA.
Why It Matters
This 8-K filing indicates that Allarity Therapeutics is making disclosures to the SEC, which could include material information relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain immediate negative or positive news.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- March 25, 2024 (date) — Earliest event reported
- March 26, 2024 (date) — Date of report
- 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing on March 25, 2024?
The filing does not specify the exact event that triggered the 8-K, only that it was reported on March 26, 2024, and the earliest event reported was March 25, 2024.
What are the main items covered in this 8-K filing?
This 8-K filing covers Regulation FD Disclosure and Financial Statements and Exhibits.
Where are Allarity Therapeutics' principal executive offices located?
Allarity Therapeutics' principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the state of incorporation for Allarity Therapeutics?
Allarity Therapeutics is incorporated in Delaware.
What is the company's telephone number?
The company's telephone number is (401) 426-4664.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-03-26 08:05:34
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0202526-8k_allarity.htm (8-K) — 24KB
- ea020252601ex99-1_allarity.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 3KB
- image_003.jpg (GRAPHIC) — 3KB
- 0001213900-24-025777.txt ( ) — 221KB
- allr-20240325.xsd (EX-101.SCH) — 3KB
- allr-20240325_lab.xml (EX-101.LAB) — 33KB
- allr-20240325_pre.xml (EX-101.PRE) — 22KB
- ea0202526-8k_allarity_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 25, 2024, Allarity Therapeutics, Inc., a Delaware corporation ("we," "our," or the "Company"), issued a press release announcing that we have been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the "Bid Price Rule") and 5550(b)(1) (the "Equity Rule") or any of the alternative requirements in Listing Rule 5550(b). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933, as amended or the Exchange Act. By furnishing this information on this Current Report on Form 8-K, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Description 99.1 Press Release, dated March 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: March 26, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer